RNA-based translation activators for targeted gene upregulation

Area of Science:

• Molecular Biology
• RNA Therapeutics
• Gene Expression Regulation

Background:

• Gene expression insufficiency underlies various diseases.
• Current therapeutic strategies often focus on gene replacement or silencing.
• A need exists for technologies that can precisely upregulate protein production.

Purpose of the Study:

• To introduce translation-activating RNAs (taRNAs) as a novel bifunctional RNA technology.
• To demonstrate taRNAs' ability to bind specific mRNAs and enhance translation.
• To validate taRNAs for therapeutic applications, including in disease models.

Main Methods:

• Designing and constructing taRNAs using internal ribosome entry sites (IRES).
• Minimizing taRNA scaffold size and identifying key protein factors.
• Validating taRNA efficacy in patient-derived cells by amplifying SYNGAP1 expression.
• Testing in vivo delivery using lipid nanoparticles (LNPs) in cell lines, neurons, and mouse liver.

Main Results:

• taRNAs successfully bind target mRNAs and directly upregulate translation.
• The technology was validated by amplifying SYNGAP1 expression in patient cells.
• Efficient delivery of taRNAs was achieved in vitro and in vivo using LNPs.

Conclusions:

• taRNAs represent a general, compact, and programmable nucleic acid-based technology.
• This approach offers a novel strategy to upregulate endogenous protein production.
• taRNAs hold promise for developing new RNA-based therapeutics for genetic disorders.